Know Cancer

or
forgot password

An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001


Phase 1/Phase 2
18 Years
N/A
Open (Enrolling by invite only)
Both
Melanoma

Thank you

Trial Information

An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001


Inclusion Criteria:



- Patient was previously enrolled in Study IMM 101 001

- Patient gives consent to make their disease and treatment history for the intervening
period between their completion of Study IMM-101-001 and enrollment in this study
available to the Sponsor

- Patient gives signed informed consent for participation in the study

Exclusion Criteria:

- Female patient of child-bearing potential who is not, in the opinion of the
Investigator, using an approved method of birth control (e.g., physical barrier
[patient and partner], contraceptive pill or patch, spermicide and barrier, or
intrauterine device [IUD]).

Those patients that utilise hormonal contraceptives must have used the same method for at
least three months before additional barrier contraception (as described above) is
discontinued from being used concomitantly with the hormonal contraception.

- Patient of non-child-bearing potential are defined as having 12 month amenorrhoea or
are surgically sterile.

- Female patient who is pregnant, breast feeding or planning a pregnancy during the
course of the study. A pre-treatment urine pregnancy test measuring human chorionic
gonadotrophin (hCG) must be negative.

- Patient is unable or unwilling to comply with the protocol.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety

Outcome Description:

Local and systemic toxicities Adverse events

Outcome Time Frame:

24 months

Safety Issue:

Yes

Principal Investigator

Angus Dalgleish, Professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

St George's, University of London

Authority:

United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study ID:

IMM-101-008

NCT ID:

NCT01559818

Start Date:

February 2012

Completion Date:

Related Keywords:

  • Melanoma
  • Melanoma

Name

Location